FROM THE EDITOR
Welcome to the Metastatic HER2-Positive Breast Cancer Resource Center! Take a look around and find current information, news, literature, and other resources from this area of oncology treatment. We hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.
Sarah Donahue, MPH, ANP, AOCNP
Carol Franc Buck Breast Cancer Center
University of California, San Francisco
Resources
DESTINY-Breast03
ASCO/COP Clinical Practice Guideline: Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
NALA
CONTROL: Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
CLEOPATRA Final OS Data (2013): Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
News & Literature Highlights